Skip to main content

Genome-Based Diagnostics Clarifying Pathways to Clinical Use: Workshop Summary (2012) / Chapter Skim
Currently Skimming:

4 Patients
Pages 29-32

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 29...
... It is survivor led -- its bylaws require that a majority of the board of directors have a personal cancer diagnosis -- and it has created and promoted the language of "cancer survivorship" as an alternative to "patient" or "victim." Mark Gorman of NCCS noted that cancer survivors have rising expectations with respect to genomic and other tests. They see these technologies as potentially guiding them toward more effective treatment and reducing the time they spend on ineffective therapies.
Read the entire page →
From page 30...
... NCCS is also very concerned about finding ways for people with cancer to get their questions answered by health care providers at the point of clinical decision making. Cancer treatment planning is a very complex process that is becoming even more complex.
Read the entire page →
From page 31...
... 31 PATIENTS Finally, Gorman pointed out that cancer survivors have become very frustrated with conversations about how to bring the best care models and goals to widespread use that begin with the question, How can it be paid for? "Personally, I prefer a dialogue that begins with the question, ‘What do patients and cancer survivors need?
Read the entire page →

Key Terms

  • genomic diagnostic
  • clinical decision
  • diagnostic tests
  • cancer care
  • reduce uncertainty

  • gorman warned
  • mark gorman
  • avoid setbacks
  • properly vetted
  • slow progress

  • investigational interventions
  • coordinated care
  • patient trust
  • clinical practice
  • quality cancer

  • enter clinical
  • entire care
  • cancer survivor
  • companion diagnostics
  • requires coordinated

  • nccs noted
  • complex process
  • fda oversight
  • regulatory pathway
  • delay progress

  • supports vigorous
  • vigorous fda
  • national coalition
  • regulatory environment
  • treatment planning


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.